Special Feature

User Panel

My Panel

My Panel

Bookmark Science Articles

Recent News
Bookmark / Share This Science Site

Olanzapine and fluoxetine administration and coadministration increase rat hippocampal pregnenolone, allopregnanolone and peripheral deoxycorticosterone: implications for therapeutic actions.

Olanzapine and fluoxetine administration and coadministration increase rat hippocampal pregnenolone, allopregnanolone and peripheral deoxycorticosterone: implications for therapeutic actions. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

  • Abstract Text of This Paper
  • Journal Published
  • MeSH Keywords of This Abstract
  • Chemicals and Substances Used in this Paper
  • Grants and Granting Agency of this Research
  • Database Accession Numbers Used in this Paper
  • Related Papers
  • Related Research Tags
  • Rate this Research Paper
  • Olanzapine and fluoxetine administration and coadministration increase rat hippocampal pregnenolone, allopregnanolone and peripheral deoxycorticosterone: implications for therapeutic actions. Abstract Text:

    christine e marxChristine E Marx,lawrence j shampineLawrence J Shampine,rahul t khistiRahul T Khisti,william t trostWilliam T Trost,daniel w bradfordDaniel W Bradford,a chistina grobinA Chistina Grobin,mark w massingMark W Massing,roger d madisonRoger D Madison,marian i butterfieldMarian I Butterfield,jeffrey a liebermanJeffrey A Lieberman,a leslie morrowA Leslie Morrow,

    Olanzapine and fluoxetine elevate the GABAergic neuroactive steroid allopregnanolone to physiologically relevant concentrations in rodent cerebral cortex. It is unknown if these agents also alter pregnenolone or deoxycorticosterone. Since olanzapine and fluoxetine in combination have clinical utility and may demonstrate synergistic effects, we investigated neuroactive steroid alterations following olanzapine, fluoxetine or coadministration. Male rats received IP vehicle, olanzapine, fluoxetine or the combination of both agents in higher-dose (0, 10, 20 or 10/20 mg/kg, respectively) and lower-dose (0, 5, 10 or 5/10 mg/kg, respectively) experiments. Pregnenolone and allopregnanolone levels in hippocampus were determined by gas chromatography/mass spectrometry. Peripheral deoxycorticosterone and other steroid levels were determined by radioimmunoassay. Olanzapine, fluoxetine or the combination increased hippocampal pregnenolone and serum deoxycorticosterone in both higher- and lower-dose experiments, and elevated hippocampal allopregnanolone in higher-dose conditions. No synergistic effects on pregnenolone or allopregnanolone were observed following olanzapine and fluoxetine coadministration compared to either compound alone. Pregnenolone and its sulfate enhance learning and memory in rodent models, and therefore pregnenolone elevations may be relevant to cognitive changes in psychotic and affective disorders. Since pregnenolone decreases have been linked to depression, it is possible that olanzapine- and fluoxetine-induced pregnenolone elevations may contribute to the antidepressant actions of these agents.

    Olanzapine and fluoxetine administration and coadministration increase rat hippocampal pregnenolone, allopregnanolone and peripheral deoxycorticosterone: implications for therapeutic actions. Publishing Authors By Initials

    ce marxCE Marx,lj shampineLJ Shampine,rt khistiRT Khisti,wt trostWT Trost,dw bradfordDW Bradford,ac grobinAC Grobin,mw massingMW Massing,rd madisonRD Madison,mi butterfieldMI Butterfield,ja liebermanJA Lieberman,al morrowAL Morrow,

    For similar chemical actions and uses: pharmacologic actions: molecular mechanisms of pharmacological action: neurotransmitter agents: neurotransmitter uptake inhibitors: serotonin uptake inhibitors research abstracts see: chemical actions and uses: pharmacologic actions: molecular mechanisms of pharmacological action: neurotransmitter agents: neurotransmitter uptake inhibitors: serotonin uptake inhibitors research

    PUBMED ID PMID:

    MEDLINE DATE:

    Olanzapine and fluoxetine administration and coadministration increase rat hippocampal pregnenolone, allopregnanolone and peripheral deoxycorticosterone: implications for therapeutic actions. Journal Published:

    PUBLICATION TYPE: Research Support, U.S. Gov't,

    Journal: Pharmacology, biochemistry, and behavior

    VOLUME: 84

    Page Numbers: 609-17

    Journal Abbreviation: Pharmacol. Biochem. Behav.

    ISSN: 0091-3057

    DAY: 20

    MONTH: 09

    YEAR: 2006

    Olanzapine and fluoxetine administration and coadministration increase rat hippocampal pregnenolone, allopregnanolone and peripheral deoxycorticosterone: implications for therapeutic actions. Information

    Number of References:

    LANGUAGE: eng

    NlmUniqueID: 367050

    Olanzapine and fluoxetine administration and coadministration increase rat hippocampal pregnenolone, allopregnanolone and peripheral deoxycorticosterone: implications for therapeutic actions. Keywords Mesh Terms:

    KEYWORDS: Serotonin Uptake Inhibitors

    MESH TERMS: pharmacology

    Chemical & Substance for Abstract: Olanzapine and fluoxetine administration and coadministration increase rat hippocampal pregnenolone, allopregnanolone and peripheral deoxycorticosterone: implications for therapeutic actions. Information

    Substance Name: Desoxycorticosterone

    Registry Number: 64-85-7

    Grant and Affiliation Information for Olanzapine and fluoxetine administration and coadministration increase rat hippocampal pregnenolone, allopregnanolone and peripheral deoxycorticosterone: implications for therapeutic actions.

    AFFILIATION: Duke University Medical Center, Durham NC, New York, NY, USA. marx0001@mc.duke.edu

    Country: United States

    United States Research PublicationUnited States Research Publication

    AGENCY: United States NIMH

    GRANT: K23 MH 65080

    ACRONYM: MH

    MEDLINETA: Pharmacol Biochem Behav

    REFSOURCE:

    DATABASENAME:

    ACCESSION NUMBER:

    Number Hits: 0

    Olanzapine and fluoxetine administration and coadministration increase rat hippocampal pregnenolone, allopregnanolone and peripheral deoxycorticosterone: implications for therapeutic actions Related Publications

     

    Molecular Station USER Menu

    Welcome to Molecular Station!

    You have to register before you can post on our forums or use our advanced features. Register Now! Its Free and Fast!

    Already registered? Login now below.

    User Name:

    Password:

    Already registered and Forgot your password? Click below to recover it.

    Recover Lost Password

    Join now - it's fast and free!

    Molecular Station is THE largest network of researchers, scientists and science lovers anywhere!

    Research Terms of Usage and Disclaimer
    Home
    Features

    Protocols

    DNA Forum

    Science Forum

    DNA Forum
    Biology Forum

    Science News


    [CaRP] XML error: Invalid document end at line 2

    For more click here:Science News